Cancer is a major health problem in the European Union (EU), and colorectal cancer (CRC) is the third most prevalent tumour..
To combat this, the EU has enforced important R&D measures such as Europe’s Beating Cancer Plan and the EU Mission: Cancer. However, the alarming numbers of new reported CRC cases in the EU-27 and the lives it claims are expected to rise by 27% in the next two decades due to various factors.
To address this, we need immediate solutions to better prevent, treat, and manage CRC.
One solution is liquid biopsy, which allows for a less invasive way to assess tumor molecular features. Despite a plethora of published CRC biomarkers, there is still a need to identify and develop novel, clinically useful biomarkers that can improve disease outcome.
There are still many unknowns about the patient-specific biological determinants of tumour initiation and dissemination, or how clonality affects disease progression and response. In addition, the lack of standardisation and reproducibility of the assays and the need for biomarker research sustainability beyond a project are also issues.
